World journal of gastrointestinal surgery · 2025
Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Xiao-Jing, Zheng Xiao, Wang Kai
Аннотация
BACKGROUND: Existing assessment systems for chronic hepatitis B (CHB)-associated liver fibrosis (LF) exhibit insufficient accuracy, thereby requiring further improvements.
AIM: To investigate the association of LF staging with hepatitis B core antibody (HBcAb), hepatitis B virus DNA (HBV-DNA), and hepatitis B surface antigen (HBsAg) in patients with CHB.
METHODS: We selected 120 patients with CHB receiving treatment in Hangzhou Linping District First People's Hospital from January 2020 to June 2024. Participants were allocated into the mild (F0-F1, n = 52) and moderate-to-severe groups (F2-F4, n = 68) following the rigorous LF staging criteria. HBcAb, HBV-DNA, and HBsAg concentrations were measured. Pearson correlations were employed to examine the correlations of HBcAb with HBV-DNA and HBsAg, whereas Spearman correlation analysis was conducted to identify the associations of the three with LF staging. Receiver operating characteristic (ROC) curves were further used to analyze the performance of these biomarkers in diagnosing LF stages. Furthermore, binary logistic regression analysis was conducted to determine the association of these three with LF progression in CHB.
RESULTS: Markedly increased HBcAb and notably decreased HBV-DNA and HBsAg were observed in moderate-to-severe cases vs their mild counterparts. A positive correlation was observed between HBV-DNA and HBsAg, whereas both markers were inversely associated with HBcAb. Moreover, LF staging exhibited a significant positive correlation with HBcAb and an inverse connection with HBV-DNA and HBsAg. The receiver operating characteristic analysis revealed area under the curve values of 0.715, 0.799, and 0.662 for HBcAb, HBV-DNA, and HBsAg in diagnosing LF staging, respectively. Combining these markers improved the area under the curve to 0.851. The final analysis identified HBcAb as promoting fibrosis advancement (odds ratio = 2.765), whereas HBV-DNA demonstrated protective properties (odds ratio = 0.247).
CONCLUSION: HBcAb is negatively correlated with HBV-DNA and HBsAg but positively associated with LF staging. All three markers are valuable in assessing LF staging, and their combined use presents the highest diagnostic efficacy. Importantly, a high HBcAb/low HBV-DNA profile markedly increased fibrosis progression risks in CHB-affected individuals.
AIM: To investigate the association of LF staging with hepatitis B core antibody (HBcAb), hepatitis B virus DNA (HBV-DNA), and hepatitis B surface antigen (HBsAg) in patients with CHB.
METHODS: We selected 120 patients with CHB receiving treatment in Hangzhou Linping District First People's Hospital from January 2020 to June 2024. Participants were allocated into the mild (F0-F1, n = 52) and moderate-to-severe groups (F2-F4, n = 68) following the rigorous LF staging criteria. HBcAb, HBV-DNA, and HBsAg concentrations were measured. Pearson correlations were employed to examine the correlations of HBcAb with HBV-DNA and HBsAg, whereas Spearman correlation analysis was conducted to identify the associations of the three with LF staging. Receiver operating characteristic (ROC) curves were further used to analyze the performance of these biomarkers in diagnosing LF stages. Furthermore, binary logistic regression analysis was conducted to determine the association of these three with LF progression in CHB.
RESULTS: Markedly increased HBcAb and notably decreased HBV-DNA and HBsAg were observed in moderate-to-severe cases vs their mild counterparts. A positive correlation was observed between HBV-DNA and HBsAg, whereas both markers were inversely associated with HBcAb. Moreover, LF staging exhibited a significant positive correlation with HBcAb and an inverse connection with HBV-DNA and HBsAg. The receiver operating characteristic analysis revealed area under the curve values of 0.715, 0.799, and 0.662 for HBcAb, HBV-DNA, and HBsAg in diagnosing LF staging, respectively. Combining these markers improved the area under the curve to 0.851. The final analysis identified HBcAb as promoting fibrosis advancement (odds ratio = 2.765), whereas HBV-DNA demonstrated protective properties (odds ratio = 0.247).
CONCLUSION: HBcAb is negatively correlated with HBV-DNA and HBsAg but positively associated with LF staging. All three markers are valuable in assessing LF staging, and their combined use presents the highest diagnostic efficacy. Importantly, a high HBcAb/low HBV-DNA profile markedly increased fibrosis progression risks in CHB-affected individuals.